Related news from |
Wed, 01 May 2024 11:40:09 +0000 |
Techne (TECH) Q3 Earnings and Revenues Beat Estimates
Techne (TECH) delivered earnings and revenue surprises of 4.35% and 3.77%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
|
Wed, 01 May 2024 10:00:00 +0000 |
Exact Sciences to Participate in May Investor Conference
MADISON, Wis., May 01, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast.
|
Wed, 24 Apr 2024 22:15:15 +0000 |
Exact Sciences (EXAS) Stock Drops Despite Market Gains: Important Facts to Note
In the latest trading session, Exact Sciences (EXAS) closed at $63.24, marking a -0.46% move from the previous day.
|
Wed, 24 Apr 2024 11:16:48 +0000 |
Here’s Why Baron Health Care Fund Reduced Exact Sciences Corporation (EXAS)
Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2024 investor letter. A copy of the same can be downloaded here. The fund advanced 8.92% (Institutional Shares) in the quarter compared to an 8.52% gain for the Russell 3000 Health Care Index (benchmark) and a 10.56% increase for the S&P […]
|
Mon, 22 Apr 2024 16:44:00 +0000 |
Should You Buy Exact Sciences (EXAS) Ahead of Q1 Earnings?
Exact Sciences' (EXAS) first-quarter 2024 performance is expected to include gains from robust Cologuard uptake and continuing Oncotype DX growth, offset slightly by increasing operating costs.
|
Mon, 22 Apr 2024 15:10:59 +0000 |
10 Best Performing Biotech ETFs in 2024
In this article, we discuss the 10 best performing biotech ETFs in 2024. If you want to skip our detailed introduction to the biotech industry and just want to take a look at some more ETFs, go directly to the 5 Best Performing Biotech ETFs in 2024. Biotechnology is a challenging field, not ideal for […]
|
Wed, 17 Apr 2024 22:15:18 +0000 |
Why Exact Sciences (EXAS) Dipped More Than Broader Market Today
Exact Sciences (EXAS) concluded the recent trading session at $63.22, signifying a -1% move from its prior day's close.
|
Wed, 17 Apr 2024 15:07:22 +0000 |
Exact Sciences Corporation's (NASDAQ:EXAS) Profit Outlook
With the business potentially at an important milestone, we thought we'd take a closer look at Exact Sciences...
|
Mon, 15 Apr 2024 10:52:00 +0000 |
Exact Sciences names Aaron Bloomer CFO
The executive will succeed Jeff Elliott, who said in January he would step down due to personal reasons.
|
Mon, 15 Apr 2024 10:00:00 +0000 |
Exact Sciences Names Aaron Bloomer as New Chief Financial Officer
MADISON, Wis., April 15, 2024--Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today the appointment of Aaron Bloomer as chief financial officer (CFO), effective May 15, 2024.
|
Fri, 12 Apr 2024 11:00:04 +0000 |
Here’s Why Exact Sciences Corporation (EXAS) Declined in Q1
Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” first quarter 2024 investor letter. A copy of the same can be downloaded here. In the first quarter, the fund’s Investor Class fund ARTMX returned 10.41%, Advisor Class fund APDMX posted a return of 10.40%, and Institutional Class fund APHMX returned 10.44%, compared […]
|
Thu, 11 Apr 2024 14:00:00 +0000 |
Myriad Genetics (MYGN) Announces Favorable Research Results
Myriad Genetics' (MYGN) latest positive initial study outcome is likely to improve clinical outcomes and reduce overall healthcare costs.
|
Thu, 11 Apr 2024 11:52:00 +0000 |
Zacks Investment Ideas feature highlights: Exact Sciences, Kaiser Aluminum and Atmus Filtration Technologies
Exact Sciences, Kaiser Aluminum and Atmus Filtration Technologies are part of the Zacks Investment Ideas article.
|
Thu, 11 Apr 2024 10:00:00 +0000 |
Exact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes
MADISON, Wis., April 11, 2024--Exact Sciences Corp. (Nasdaq: EXAS) (the "Company"), a leading provider of cancer screening and diagnostic tests, today announced that on April 10, 2024 it entered into privately negotiated exchange and purchase agreements (the "Agreements") with certain holders of the Company’s 0.3750% Convertible Senior Notes due 2028 (the "Existing Notes"). Pursuant to the Agreements, the Company has agreed to issue to the holders $620.7 million aggregate principal amount of a n
|
Wed, 10 Apr 2024 22:15:19 +0000 |
Exact Sciences (EXAS) Stock Moves -0.89%: What You Should Know
Exact Sciences (EXAS) closed at $73.60 in the latest trading session, marking a -0.89% move from the prior day.
|
Wed, 10 Apr 2024 19:27:00 +0000 |
3 Buy-Rated Stocks Flexing Relative Strength
While the market has taken a small breather as of late, there have been many big-time winners throughout the last month, including these three. Analysts are bullish on their outlooks, with all three carrying a favorable Zacks Rank.
|
Wed, 10 Apr 2024 12:16:00 +0000 |
Search for Cancer Blood Test Continues Despite Illumina-Grail Deal’s Failure
Investors shelved their hopes for a pioneering cancer blood test after Illumina ‘s $8 billion acquisition of start-up Grail was scuttled by antitrust regulators last year. A decade from now, these blood tests could be used to flag the more than 60% of deadly cancers that currently lack any way to screen for them. At the annual meeting of the American Association for Cancer Research in San Diego, Exact Sciences reported on a 6,000-sample study of a multi-cancer test it plans to offer alongside single-cancer screening products such as its well-known Cologuard stool-based test for colon cancer.
|
Wed, 10 Apr 2024 04:00:45 +0000 |
ZTS, EXAS, AZN: Which Biotech Stock Is the Better Buy?
Despite the market’s hot year-to-date run, there’s no shortage of affordable stocks that also have impressive growth profiles. In the biotech scene, numerous firms can harness a technological edge to improve various aspects of health and medicine. From genetic medicine to less-invasive disease diagnostics, this piece will check out three Strong-Buy-rated stocks—ZTS, EXAS, and AZN—that I view as among the most investable in the often-choppy biopharmaceutical scene. Though individual biotech and b
|
Tue, 09 Apr 2024 11:37:17 +0000 |
11 Best Biotech ETFs To Buy
In this article, we discuss 11 best biotech ETFs to buy. If you want to skip our discussion on the biotech industry, head over to 5 Best Biotech ETFs To Buy. The new era in biotech is defined by the convergence of biology, data, and artificial intelligence. According to The Journal of mHealth, the focus […]
|
Mon, 08 Apr 2024 16:05:00 +0000 |
Exact Sciences to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR Annual Meeting 2024
MADISON, Wis., April 08, 2024--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present late-breaking data from the first analysis of the ASCEND-2 study demonstrating the compelling performance of its investigational multi-biomarker class, multi-cancer early detection (MCED) blood test. These results validate the sensitivity and specificity of the company’s multi-biomarker class approach across a broad range of cancer types, including the mos
|